Bovine herpesvirus-4 based vaccine provides protective immunity against Streptococcus suis disease in a rabbit model

Dong, N. et al. (2023) Bovine herpesvirus-4 based vaccine provides protective immunity against Streptococcus suis disease in a rabbit model. Vaccines, 11(5), 1004. (doi: 10.3390/vaccines11051004) (PMID:37243109) (PMCID:PMC10222682)

[img] Text
299777.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Streptococcus suis (S. suis) is a bacterial pathogen of pigs that has a major animal health and economic impact on the pig industry. Bovine herpesvirus-4 (BoHV-4) is a new virus-based vaccine vector that has been used for the immunogenic delivery of antigens from a variety of pathogens. In the present study, two recombinant BoHV-4-based vectors were evaluated for their ability to induce immunity and protection against S. suis in a rabbit model. The GMD protein is a fusion protein consisting of multiple dominant B-cell epitopes ((B-cell dominant epitopes of GAPDH, MRP, and DLDH antigens) (BoHV-4/GMD)) and the second suilysin (SLY) (BoHV-4/SLY) from S. suis serotype 2 (SS2). Both GMD and SLY delivered by the BoHV-4 vectors were recognized by sera from SS2-infected rabbits. The vaccination of rabbits with the BoHV-4 vectors induced antibodies against SS2, as well as against additional S. suis serotypes, SS7 and SS9. However, sera from BoHV-4/GMD-vaccinated animals promoted a significant level of phagocytic activity by pulmonary alveolar macrophages (PAMs) against SS2, SS7, and SS9. In contrast, sera from rabbits immunized with BoHV-4/SLY induced PAM phagocytic activity against only SS2. In addition, BoHV-4 vaccines differed in the associated level of protection against lethal SS2 challenge, which ranged from high (71.4%) to low (12.5%) for BoHV-4/GMD and BoHV-4/SLY, respectively. These data suggest BoHV-4/GMD as a promising vaccine candidate against S. suis disease.

Item Type:Articles
Additional Information:This research was funded by the National Key Research and Development Program of China (No. 2018YFE0101300) and the Department of Health and Social Care, UK (No. IUK 104985).
Keywords:Streptococcus suis, BoHV-4, GMD, suilysin, serotype, vector-based vaccine, protection.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Davison, Professor Andrew
Authors: Dong, N., Nichols, H., Sun, Q., Chen, X., Zheng, J., Guan, Z., Zhang, H., Davison, A., Wezel, Y., Li, Z., Li, B., Liu, K., Shao, D., Qiu, Y., Sun, J., Li, X., Upton, M., Ma, Z., Jarvis, M. A., and Wei, J.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Vaccines
Publisher:MDPI
ISSN:2076-393X
ISSN (Online):2076-393X
Published Online:20 May 2023
Copyright Holders:Copyright © 2023 The Authors
First Published:First published in Vaccines 11(5): 1004
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record